Inflammatory subgroups of schizophrenia and their association with brain structure: A semi-supervised machine learning examination of heterogeneity

[1]  John A. Williams,et al.  Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders , 2022, JAMA psychiatry.

[2]  Peter B. Jones,et al.  Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers , 2022, Psychological Medicine.

[3]  C. Weickert,et al.  Maternal immune activation with high molecular weight poly(I:C) in Wistar rats leads to elevated immune cell chemoattractants , 2022, Journal of Neuroimmunology.

[4]  O. Lutz,et al.  Inflammatory Subtypes in Antipsychotic-Naïve First-Episode Schizophrenia are Associated with Altered Brain Morphology and Topological Organization , 2021, Brain, Behavior, and Immunity.

[5]  Peter B. Jones,et al.  Associations of Immunological Proteins/Traits with Schizophrenia, Major Depression and Bipolar Disorder: A Bi-Directional Two-Sample Mendelian Randomization Study , 2021, Brain, Behavior, and Immunity.

[6]  B. Misiak,et al.  A Meta-Analysis of the Influence of Antipsychotics on Cytokines Levels in First Episode Psychosis , 2021, Journal of clinical medicine.

[7]  M. Leboyer,et al.  Identification of inflammatory subgroups of schizophrenia and bipolar disorder patients with HERV-W ENV antigenemia by unsupervised cluster analysis , 2021, Translational Psychiatry.

[8]  A. Zalesky,et al.  Brain morphology is differentially impacted by peripheral cytokines in schizophrenia-spectrum disorder , 2021, Brain, Behavior, and Immunity.

[9]  A. Zalesky,et al.  Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions , 2021, European Archives of Psychiatry and Clinical Neuroscience.

[10]  C. Pantelis,et al.  Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study , 2021, Neuropsychopharmacology.

[11]  M. Leboyer,et al.  Natural killer cells in first-episode psychosis: an innate immune signature? , 2021, Molecular Psychiatry.

[12]  G. Pearlson,et al.  Multivariate Relationships Between Peripheral Inflammatory Marker Subtypes and Cognitive and Brain Structural Measures in Psychosis , 2020, Molecular Psychiatry.

[13]  T. Purves-Tyson,et al.  Increased Macrophages and C1qA, C3, C4 Transcripts in the Midbrain of People With Schizophrenia , 2020, Frontiers in Immunology.

[14]  M. Tremblay,et al.  The Inflamed Brain in Schizophrenia: The Convergence of Genetic and Environmental Risk Factors That Lead to Uncontrolled Neuroinflammation , 2020, Frontiers in Cellular Neuroscience.

[15]  E. Loth,et al.  Interferon-γ signaling in human iPSC–derived neurons recapitulates neurodevelopmental disorder phenotypes , 2020, Science Advances.

[16]  G. Fond,et al.  The Role of Inflammation in the Treatment of Schizophrenia , 2020, Frontiers in Psychiatry.

[17]  S. Lui,et al.  Association of peripheral cytokine levels with cerebral structural abnormalities in schizophrenia , 2019, Brain Research.

[18]  A. Falini,et al.  Natural killer cells protect white matter integrity in bipolar disorder , 2019, Brain, Behavior, and Immunity.

[19]  G. Pearlson,et al.  Association of Choroid Plexus Enlargement With Cognitive, Inflammatory, and Structural Phenotypes Across the Psychosis Spectrum. , 2019, The American journal of psychiatry.

[20]  Y. Fang,et al.  Integrative analyses of major histocompatibility complex loci in the genome-wide association studies of major depressive disorder , 2019, Neuropsychopharmacology.

[21]  F. Dickerson,et al.  Schizophrenia is Associated With an Aberrant Immune Response to Epstein–Barr Virus , 2018, Schizophrenia bulletin.

[22]  O. Howes,et al.  A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis , 2018, Schizophrenia bulletin.

[23]  Peter B. Jones,et al.  The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial , 2018, The lancet. Psychiatry.

[24]  R. Lenroot,et al.  C-Reactive Protein: Higher During Acute Psychotic Episodes and Related to Cortical Thickness in Schizophrenia and Healthy Controls , 2018, Front. Immunol..

[25]  C. Carter,et al.  Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms , 2018, Journal of Neuroinflammation.

[26]  A. Zalesky,et al.  Widespread Volumetric Reductions in Schizophrenia and Schizoaffective Patients Displaying Compromised Cognitive Abilities , 2018, Schizophrenia bulletin.

[27]  N. Arsenijević,et al.  Interleukin-6 in Schizophrenia—Is There a Therapeutic Relevance? , 2017, Front. Psychiatry.

[28]  R. Lenroot,et al.  Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder , 2017, Journal of Neuroinflammation.

[29]  C. Pantelis,et al.  Ventricular volumes across stages of schizophrenia and other psychoses , 2017, The Australian and New Zealand journal of psychiatry.

[30]  J. Rybakowski,et al.  Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review , 2017, Schizophrenia Research.

[31]  Christos Davatzikos,et al.  HYDRA: Revealing heterogeneity of imaging and genetic patterns through a multiple max-margin discriminative analysis framework , 2017, NeuroImage.

[32]  Peter B. Jones,et al.  Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study , 2017, Brain, Behavior, and Immunity.

[33]  J. Kril,et al.  Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation , 2016, Translational Psychiatry.

[34]  H. Lachman,et al.  The Major Histocompatibility Complex (MHC) in Schizophrenia: A Review , 2016, Journal of clinical & cellular immunology.

[35]  B. Aouizerate,et al.  Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. , 2016, Schizophrenia bulletin.

[36]  V. Steen,et al.  The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis , 2016, BMC Psychiatry.

[37]  Giulio Genovese,et al.  Schizophrenia risk from complex variation of complement component 4 , 2016, Nature.

[38]  T. Nevidimova,et al.  Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia , 2015, Acta Neuropsychiatrica.

[39]  Xiaoping P. Hu,et al.  Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression , 2015, Molecular Psychiatry.

[40]  M. Maes,et al.  High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance , 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[41]  R. Lenroot,et al.  Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume , 2015, Molecular Psychiatry.

[42]  Peter B. Jones,et al.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. , 2015, The lancet. Psychiatry.

[43]  Tyrone D. Cannon,et al.  Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project , 2014, Schizophrenia bulletin.

[44]  V. Cropley,et al.  Using longitudinal imaging to map the ‘relapse signature’ of schizophrenia and other psychoses , 2014, Epidemiology and Psychiatric Sciences.

[45]  N. Barnes,et al.  Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.

[46]  Yufeng Liu,et al.  Statistical Significance of Clustering Using Soft Thresholding , 2013, Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America.

[47]  M. Cairns,et al.  Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia , 2013, Molecular Psychiatry.

[48]  Anthony A. Grace,et al.  Dopamine system dysregulation by the hippocampus: Implications for the pathophysiology and treatment of schizophrenia , 2012, Neuropharmacology.

[49]  B. Kirkpatrick,et al.  Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects , 2011, Biological Psychiatry.

[50]  Alex Fornito,et al.  Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. , 2009, Schizophrenia bulletin.

[51]  Ulrich Schall,et al.  Australian Schizophrenia Research Bank: A Database of Comprehensive Clinical, Endophenotypic and Genetic Data for Aetiological Studies of Schizophrenia , 2009, The Australian and New Zealand journal of psychiatry.

[52]  Patricia Desmond,et al.  Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. , 2006, Archives of general psychiatry.

[53]  G. Valuri,et al.  The diagnostic interview for psychoses (DIP): development, reliability and applications , 2005, Psychological Medicine.

[54]  M. Callan.  The immune response to Epstein-Barr virus. , 2004, Microbes and infection.

[55]  D. Garver,et al.  Brain and ventricle instability during psychotic episodes of the schizophrenias , 2000, Schizophrenia Research.

[56]  D Castle,et al.  Psychotic Disorders in Urban Areas: An Overview of the Study on Low Prevalence Disorders , 2000, The Australian and New Zealand journal of psychiatry.

[57]  C. Pantelis,et al.  Hippocampal volume in first-episode psychoses and chronic schizophrenia: a high-resolution magnetic resonance imaging study. , 1999, Archives of general psychiatry.

[58]  C. Randolph,et al.  The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. , 1998, Journal of clinical and experimental neuropsychology.

[59]  B. Miller,et al.  C-reactive protein levels in schizophrenia: a review and meta-analysis. , 2014, Clinical schizophrenia & related psychoses.

[60]  P. M. Guffin,et al.  The diagnostic interview for psychoses (DIP) : development, reliability and applications , 2006 .

[61]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[62]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[63]  L. Hubert,et al.  Comparing partitions , 1985 .